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ABSTRACT 
Introduction: Patients post sepsis syndromes have a 
poor quality of life and a high rate of recurring illness 
or mortality. Follow-up clinics have been instituted for 
patients postgeneral intensive care but evidence is 
sparse, and there has been no clinic specifically for 
survivors of sepsis. The aim of this trial is to 
investigate if targeted screening and appropriate 
intervention to these patients can result in an improved 
quality of life (Short Form 36 health survey (SF36V.2)), 
decreased mortality in the first 12 months, decreased 
readmission to hospital and/or decreased use of health 
resources. 
Methods and analysis: 204 patients postsepsis 
syndromes will be randomised to one of the two 
groups. The intervention group will attend an 
outpatient clinic two monthly for 6 months and receive 
screening and targeted intervention. The usual care 
group will remain under the care of their physician. To 
analyse the results, a baseline comparison will be 
carried out between each group. Generalised estimating 
equations will compare the SF36 domain scores 
between groups and across time points. Mortality will 
be compared between groups using a Cox proportional 
hazards (time until death) analysis. Time to first 
readmission will be compared between groups by a 
survival analysis. Healthcare costs will be compared 
between groups using a generalised linear model. 
Economic (health resource) evaluation will be a within- 
trial incremental cost utility analysis with a societal 
perspective. 
Ethics and dissemination: Ethical approval has 
been granted by the Royal Brisbane and Women’s 
Hospital Human Research Ethics Committee (HREC; 
HREC/13/QRBW/17), The University of Queensland 
HREC (2013000543), Griffith University (RHS/08/14/ 
HREC) and the Australian Government Department of 
Health (26/2013). The results of this study will be 
submitted to peer-reviewed intensive care journals and 
presented at national and international intensive care 
and/or rehabilitation  conferences. 
 
Strengths and limitations of this study 
 
▪ This is the first study to concentrate solely on 
patients with sepsis syndrome postintensive care 
discharge. 
▪ There is a strong multidisciplinary team to 
provide  a  multitude  of  screening  tools  and 
interventions. 
▪ Individualised management will be provided to 
patients. 
▪ This is a single-centre study, so lacks external 
generalisibility.  
 
Trial registration number: Australian and New Zealand 
Clinical Trials Registry ACTRN12613000528752. 
   
BACKGROUND 
Greater numbers of patients are surviving in 
intensive care units (ICUs) but a new syn- 
drome called the ‘post-ICU syndrome’ has 
appeared with residual physical, cognitive 
and psychosocial problems lasting from 5 to 
15 years.1 2 The rate of a major illness recur- 
ring and/or mortality is also increased in the 
year after ICU discharge, with mortality 
ranging from 26% to 63% at 1-year post- 
discharge in long-stay ICU patients (≥48 h).3 
ICU survivors additionally often have a 
number  of  problems1–4  including  debility 
and fatigue from loss of muscle mass, 
ongoing nutritional problems, difficulty in 
dealing with altered appearance and func- 
tion, chronic pain,5 amnesia and delusional 
symptoms. All of these factors have a major 
impact on the health and productivity of sur- 
vivors and their carers, survivors’ return to 
work   rates,   as   well   as   the   impact   on 
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availability of ICU and hospital beds, surgical waiting 
lists, health costs and society.6 There has been a ‘call to 
arms’ to provide improved management regimes to ICU 
survivors.7 The National Institute of Health and Care 
Excellence (NICE) clinical guidelines8 provided by the 
National Health Service (NHS) NICE recommend ‘opti- 
misation of recovery’ rather than merely survival post-
ICU. All of these problems are particularly present in 
survivors of sepsis.9 
Sepsis is defined as a powerful inflammatory response 
to severe infection.10 The annual total cost of sepsis syn- 
dromes in the USA is $16.7 billion nationally11 with the 
incidence projected to increase by 1.5% per annum as 
patients develop more comorbidities and resistant organ- 
isms. In brief, sepsis is a major public health concern.12 
However, the statistics above do not include the cost of 
ongoing disability and loss of productivity postillness. 
Patients with sepsis syndromes have significantly worse 
outcomes with lower health-related quality of life 
(HRQoL),13–16 particularly in the physical domain,17 18 
chronic pain5 19 and cognitive domain20 compared with 
non-septic ICU survivors. While other critically ill/ 
injured or disabled patients, for example, those with 
burns, strokes, head injuries have established follow-up 
regimes, patients with sepsis are not referred to formal 
rehabilitation and are discharged home with extremely 
poor function. 
Follow-up ICU outpatient clinics are a recent innov- 
ation particularly within the UK.21–23 These clinics iden- 
tify and provide intervention for problems posthospital 
discharge including weakness, poor balance, impaired 
swallowing and nutrition, ongoing emotional problems 
and/or post-traumatic stress disorder in critical illness 
survivors. The one completed clinical trial on this topic24 
did not find a significant improvement in HRQoL. 
Researchers admitted that one discipline was not ideal 
and ‘further work should focus on the roles of early phys- 
ical rehabilitation, delirium, cognitive dysfunction and 
relatives’. The programme was conducted in a generic 
group of ICU survivors including those with only an over- 
night stay, and there may be greater discriminatory power 
in selecting only one diagnostic group with a documen- 
ted poor outcome such as sepsis syndrome. Additionally 
some countries (Canada, Australia, South Africa) have 
major problems with large land area and relatively sparse 
population in rural areas leading to a lack of resources 
and problems with follow-up post-ICU.25 
  
AIMS 
The primary aim of this research is to investigate whether 
targeted follow-up and intervention will improve HRQoL 
in survivors of sepsis syndromes. Secondary aims will be 
to investigate whether this intervention decreases 
readmission rates to hospital, 12-month mortality and 
health resource use. 
This  project  will  be  an  important  investigation  of 
follow-up  and  management  of  ICU  patients  in  a 
subpopulation (sepsis) documented to have poor out- 
comes.16 The project will incorporate a subgroup (rural 
patients) via telemedicine26 in a novel method to over- 
come the problem of the ‘tyranny of distance’ in 
follow-up. 
  
Hypotheses 
The hypotheses are that posthospital follow-up will 
improve HRQoL, decrease mortality, economic  and 
health resource  use and  readmission to hospital in 
patients postadmission to ICU with sepsis syndrome. 
 
 
METHODS/DESIGN 
This is a prospective, double-blinded, interventional, 
repeated measures, superiority, randomised controlled 
trial with concealed allocation, blinded assessors and 
intention-to-treat analysis. The study has been designed in 
accordance with the Consolidated Standards for 
Reporting of Trials guidelines27 (figure 1) and the 
Standard Protocol items: Recommendation for 
Interventional Trials (SPIRIT 2013).28 The trial will be 
completed in two outpatient clinics. One clinic will be in 
the outpatient department located at the university- 
affiliated tertiary hospital Royal Brisbane and Women’s 
Hospital (RBWH), Brisbane, Australia; the other will be 
located at a regional hospital—the Bundaberg Base 
Hospital, Bundaberg, Queensland, Australia. 
  
Participants 
Participants will be recruited from among patients being 
discharged from a quaternary university-affiliated ICU at 
RBWH, Brisbane, Australia. Participants will be rando- 
mised to one of the  two  groups  (intervention  or 
control) post-ICU discharge and just prior to discharge 
from hospital. 
  
Inclusion criteria 
Patients included will be men or women ≥18 years of 
age, with a documented episode(s) of sepsis10 (≥2 cri- 
teria of a systemic inflammatory response plus proven or 
strongly suspected infection, severe sepsis defined as 
sepsis plus organ failure, septic shock defined as severe 
sepsis not responding to management) and required 
respiratory support for longer than 48 h. Enrolment in 
the study should be within 1 month of discharge from 
hospital. 
  
Exclusion criteria 
Patients with neurological injuries, spinal injuries and 
burns will be excluded, as these patients have existing 
rehabilitation programmes and community  support 
groups. Patients with haematological conditions or 
requiring palliative care post-ICU will also be excluded. 
Patients with psychiatric and/or mental disabilities that 
preclude them from understanding the questionnaires 
and non-English speaking patients will also be excluded. 
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Figure 1    CONSORT flow 
diagram. 
 
  
 
  
 
  
 
  
 
  
 
  
 
  
 
  
   
 
 
Randomisation 
Participants will be randomised by opaque sealed envel- 
opes after enrolment. Numbers on the envelopes will be 
generated by a computer-generated randomisation 
(http://www.randomization.com) table based on blocks 
of four to assign patients to either the intervention or 
the usual care group. The randomisation sequence will 
be concealed from consent designee staff and protected 
by an electronic password. Participants will be stratified 
based on a score >3 on the Cumulative Illness Rating 
Scale (CIRS-G).29 
We are stratifying patients as most patients who 
develop sepsis syndromes have a number of comorbid- 
ities, but there can be a small number  of relatively 
young, healthy patients who are affected. The allocation 
sequence will be generated by the research assistant 
attached to the trial. Patients will be consented by the 
chief investigator ( JDP) and assigned to interventions by 
a second investigator (PT). 
 
 
INTERVENTION 
Intervention group 
Patients in the intervention group will attend a follow-up 
clinic two monthly for up  to 6 months  after discharge 
from the hospital. Screening instruments will be utilised 
on the first visit and appropriate management and refer- 
ral provided. These will involve: overall medical review 
involving all systems assessment, medications, vital signs, 
physical activity assessment, muscle strength,30 assessment 
of mobility (modified Rivermead Mobility Index),31 balance 
assessment (Berg Balance measure),32 discussion with carer 
as to concerns (Zarit Burden Interview),33 screening for 
chronic pain syndromes (Brief Pain Inventory),34 nutri- 
tional review, screening with the (PTSD) Checklist-Civilian 
Version (for post-traumatic stress syndrome),35 generalised 
anxiety disorder (GAD-7)36 and  The Patient Health 
Questionnaire-9 for depression.37 Following the results of the 
screening and team discussion, participants and/or carer 
will be referred to appropriate agencies including the 
general practitioner, specialist, physiotherapist, nutrition- 
ist, speech pathologist, exercise physiologist, psychologist 
and/or occupational therapist. These instruments are 
screens for post-ICU problems that have been identified 
in previous studies.13–20 Members of the research team 
include an intensivist/thoracic physician, two specialist 
respiratory physiotherapists, a psychologist,  a  senior 
nurse researcher, a professor of community and general 
practice and a health economist/community physiother- 
apist. This individualised management is in line with 
recommendations of the NICE clinical guidelines.8 
  
Standard care 
Patients in the control group will have usual care, that is, 
they will be referred to specialist outpatient clinics and/ 
or general practitioners on discharge. 
  
Subgroup—rural  patients 
A small number of patients (10) originally managed in 
the major quaternary level ICU will be discharged to a 
rural area. We will test the feasibility of providing 
follow-up care to these patients. These patients will also 
be randomised to either the intervention or the usual 
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care group. The patients will be interviewed via tele- 
medicine (videoconferencing)26 and a research assistant 
will be appointed to complete other screening tools and 
refer them to appropriate agencies. If specialist services 
are required, for example, chronic pain clinic, these 
may also be accessed via telemedicine. 
  
OUTCOME MEASURES 
Primary measure 
The primary measure will be HRQoL as measured by 
the Short Form 36 health survey V.2 (SF36V.2)38 which 
demonstrates content and construct validity, sensitivity 
and responsiveness to change in many patient groups39 
including ICU and postsepsis survivors.40 Pilot testing of 
the SF36 in this population by this team has been con- 
ducted in a current trial of inpatients postsepsis and has 
shown excellent completion rates at 6 months by 
telephone.41 
 
Secondary measures 
Patients’ readmission rates to hospital (medical record 
data), 12-month mortality (only expectedtrend) and eco- 
nomics and healthcare resource use. The latter will be 
monitored through examination of patient medical 
records, patient self-report  and through  Medicare/ 
Pharmaceutical Benefits Scheme data extraction. The 
SF6D42 is a preference based six-dimensional health 
state measure suitable for economic evaluation that is 
derived from the SF36. The SF6D defines 249 health 
states, and a summary utility score for the SF6D will be 
calculated using UK weights. 
Individual patient productivity will be measured using 
a work/activity impairment questionnaire, the Work 
Productivity and Activity Impairment Questionnaire 
(WPAI).43 
The outcome measure of SF36V.2 will be taken at 
baseline, 6 and 12 months postenrolment in the study. 
All other measures (mortality, hospital readmission and 
economic and health resource use) will be taken at 6 
and 12 months postenrolment. 
 
Sample size 
Power calculations are based on SF36 using previously 
published Minimally Clinically Important Differences 
(MCIDs) for the SF36 physical domain scores of 7.8 
points (SD 15) in our pilot trial on rehabilitation in 
sepsis.41 The sample size, based on a two sample com- 
parison of means was calculated at 78/group for the 
SF36 at 90% power with a two-sided, α error level of 
0.05. Allowing for an almost 30% loss to follow-up (mor- 
tality, dropouts), a total of 204 participants will be 
required.44 
 
Planned statistical analysis 
Primary outcomes 
A baseline comparison of demographics, length of stay 
in  ICU,  severity  of  illness,  Acute  Physiological  and 
Chronic Health Evaluation score (APACHE II) on 
admission to ICU45 and baseline measures will be 
carried out between each group, using a combination of 
t tests and χ2 test. 
Generalised estimating equations (GEE) will be used 
to compare the SF36 domain scores between groups and 
across time points. The GEE is a flexible technique that 
takes into account the correlations among individuals in 
longitudinal study designs and can account for missing 
data without a need for imputation techniques.46 
 
Secondary outcomes 
Mortality will be compared between groups using a Cox 
proportional hazards (time until death) analysis.47 Time 
to first readmission will be compared between groups by 
a survival analysis. Utility estimates derived from the 
SF6D will be analysed using a GEE. Healthcare costs will 
be compared between groups using a generalised linear 
model to account for the non-normal distribution. 
Economic (health resource) evaluation will be a within- 
trial incremental cost utility analysis with a societal 
perspective.48 Direct costs included will be: cost of care 
provided in hospitals, by general practitioners, home 
nursing, complementary (allied) health providers, alter- 
native health providers, opportunity  cost  of  unpaid 
carers, cost of transportation to  programme  and  to 
other health services and cost of  pharmaceuticals. 
Indirect costs include loss of productivity due to disease, 
such as time lost from work or providing informal care 
to another individual. All costs will be valued using 
market costs where available and productivity costs will 
be valued using actual patient wage rates. 
The subgroup of rural patients will be analysed in the 
full analysis and subgroup results will be compared with 
metropolitan patients. 
 
Data management 
A custom-designed database will store de-identified 
patient data on a secure password  protected  file.  This 
will be entered from hard copies of the scoring sheets. 
Data will be reviewed by research office staff twice yearly 
and cross referenced with stored hard copies. A data 
management committee comprising a senior ICU spe- 
cialist, a senior critical care nurse and a senior physio- 
therapist will review the data every 6 months. 
 
Contingencies 
If participant recruitment does not reach the required 
sample size in 2 years, the study can be extended for a 
further 1–2 years. 
 
Methods for protecting against other sources of bias 
This study will be double blinded with the assessors, data 
analysts and a number of investigators (TC, FC and GM) 
blinded from group allocation. There will be concealed 
allocation of participants. Participants will be stratified 
for CIRS-G.29 Participants when being consented will be 
told that they will be in one of the two groups which will 
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be followed up posthospital and they may need to 
attend an outpatient clinic. Patients are unaware of the 
usual follow-up posthospital so should not feel they are 
receiving an increased/decreased level of care. Both 
groups will be contacted by telephone for completion of 
HRQoL life instruments at the required stages. 
Participants may have varying severity of illness, lengths 
of stay and/or time on mechanical ventilation in ICU; 
however, this will be compared between groups and if 
unequal adjusted models using the relevant  covariates 
will be presented as well as unadjusted comparisons. 
A few participants in either group may be referred to 
rehabilitation by their treating physician. This will be 
compared between groups. A number of patients may 
be uncontactable for final outcome measures; however, 
we have had a 95% rate in the current trial at 6 months 
postsepsis.41 The GEE46 will allow for missing data. If 
patients ‘cross-over’, that is, do not receive the planned 
intervention, they will still be analysed with the group 
they originally enrolled as per intention to treat. 
  
ETHICS  AND  DISSEMINATION 
The trial has been registered on the Australian and New 
Zealand Clinical Trials Registry (ACTRN12613000528752). 
Any  adverse  events  connected  to  the  trial  will  be 
immediately reported to one of the following three com- 
mittees:  RBWH  Human  Research  Ethics  Committee, 
The University of Queensland, Griffith University and 
the Australian Government Department of Health. 
The results of this study will be submitted for publica- 
tion to peer-reviewed  ICU journals  and presented at 
national and international ICU and/or rehabilitation 
conferences. 
  
CONCLUSION 
Follow-up post-ICU stay is presently a topic of great inter- 
est with a realisation that surviving critical illness may 
result in poor quality of life. Patients who have had 
severe sepsis syndromes have been shown to have a 
poorer quality of life and outcome than generic ICU 
patients. This study will investigate whether targeted 
intervention from a multidisciplinary team will result in 
benefits and is  economically feasible for this group of 
patients. 
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